Overview


According to FutureWise analysis the market for Agoraphobia is expected to reach US$ 1.71 billion by 2031 at a CAGR of 7.12%.

Agoraphobia is an anxiety disorder that causes overwhelming fear of being trapped, helpless, or unable to find a way to escape or seek assistance. Because of fear and anxiety, an individual with agoraphobia usually avoids new places and unfamiliar situations. When confronted with a stressful situation, individuals with agoraphobia commonly exhibit panic attack symptoms, including a rapid heartbeat and feelings of nausea. They may also experience these symptoms before entering the situation they fear. In some cases, the condition can be so intense that individual avoid daily activities and stay home most of the day. For instance, according to the NIMH, approximately 0.8 percent of American adults suffer from agoraphobia, and roughly 40 percent of cases are classified as severe. When the disorder is more advanced, agoraphobia can be very disabling. Individuals with agoraphobia often realize their fear is irrational, but they cannot do anything about it.

Patients with mild or moderate panic agoraphobia can choose between psychotherapy and pharmacotherapy for adequate symptom management. Studies have generally concluded that cognitive-behavioral therapy (CBT) effectively manages and alleviates target symptoms, reduces other anxiety symptoms, and improves the patient's quality of life. For patients with more severe forms of agoraphobia or those individuals who prefer pharmacotherapy over psychotherapy, there are several effective options for medication management. Selective serotonin receptor inhibitors (SSRIs) are considered first-line therapy, with therapeutic doses being the same as depression. Serotonin-norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, and TCAs (tricyclic antidepressants) have also been effective alternatives to SSRIs in treating panic disorder and agoraphobia. SSRIs are generally preferable to these other medications because of the side effect profile, affordability, availability, decreased potential for abuse, and better tolerability.

FutureWise Market Research has published a report that provides an insightful agoraphobia market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, agoraphobia market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Eli Lilly
  • Bristol-Myers Squibb
  • AstraZeneca
  • Pfizer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Sandoz
  • Apotex
  • Mylan Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

The growing advancements in treatment modalities, including a spectrum of innovative approaches such as virtual reality exposure therapy, neurofeedback techniques, and personalized pharmacotherapy, are projected to drive the growth of the agoraphobia market during the forecast period. Advancements in research and development promise to unveil more effective treatments, varying from cutting-edge medications to innovative novel therapies. Also, virtual reality exposure therapy is a transformative intervention, offering a controlled and immersive atmosphere for individuals to confront and slowly overcome their agoraphobic triggers. Moreover, the shift towards holistic mental health approaches in the agoraphobia treatment market, including stakeholders, is acknowledging the integral role of factors like balanced nutrition, exercise, and mindfulness practices in augmenting traditional therapeutic approaches. This trend reflects a more general societal emphasis on comprehensive well-being and demand for integrated treatment solutions that address the complex nature of agoraphobia. As patients and healthcare providers adopt this approach, the market is poised to witness a surge in demand for complementary treatments and services that promote symptom relief and sustained mental health stability and vitality. Furthermore, the online and in-person communities for individuals dealing with agoraphobia offer a fundamental opportunity for mental health support. These platforms create safe spaces where individuals have the chance to openly share their experiences, challenges, and achievements, promoting a sense of connection and understanding. These communities play an essential role in the recovery journey through mutual support and shared coping strategies. They also serve as platforms for disseminating valuable resources, expert advice, and empowerment. However, the constant social stigma encompassing mental health conditions, including agoraphobia, may hinder the growth of the agoraphobia market. This stigma often leads to hesitancy in individuals to openly recognize their struggles or seek professional help. Fear of judgment or intolerance may prevent them from accessing necessary resources and support systems. Thus, many individuals may endure their condition in silence, preceding potentially life-changing treatments, further impeding the market growth.

By Type

  • Selective serotonin reuptake inhibitors
  • Norepinephrine reuptake inhibitors

By Application

  • Hospitals
  • Clinics

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the high prevalence of agoraphobia, increasing incidence of mental disorders such as depression, increased focus of the government on mental health, rising utilization of medications, such as SSRIs (selective serotonin reuptake inhibitors), benzodiazepines, beta-blockers, etc., presence of leading market players, and focus on R&D activities to develop better treatments & therapies for agoraphobia in U.S. is expected to drive the market growth over the forecast period. For instance, approximately 970 million individuals, one in every eight people, experience a mental disorder, with anxiety and depression being the most prevalent. Therefore, the factors mentioned above are further projected to propel the growth of the agoraphobia market during the forecast period in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Agoraphobia Market By Type, By Application and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Agoraphobia Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Agoraphobia Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Agoraphobia Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals and Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Agoraphobia Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Selective serotonin reuptake inhibitors
        2. Norepinephrine reuptake inhibitors

  • 8.   Global Agoraphobia Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics

  • 9.   North America Agoraphobia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Agoraphobia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Agoraphobia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Agoraphobia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Agoraphobia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Eli Lilly
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bristol-Myers Squibb
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson & Johnson
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sandoz
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Apotex
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Mylan Pharmaceuticals
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Agoraphobia Treatment Market

Read More
Partner

Our Clients